Trial Profile
Study of the inter-individual variation of PhArmaCo-kinetics of InFliximab during treatment Induction in patients with Crohn's disease and Ulcerative Colitis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Pharmacokinetics
- Acronyms PACIFIC
- 18 Jul 2016 New trial record